{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:54Z","timestamp":1787721714596,"version":"build-2784847793"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The development of acquired resistance to cyclin-dependent kinase 4\/6 inhibitors (CDK4\/6i) represents a major clinical challenge in the management of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Overcoming this resistance requires novel therapeutic strategies that target the underlying molecular escape pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>We report the case of a patient initially diagnosed in 2011 with pT2N0M0, ER+\/HER2- invasive ductal carcinoma. Following multimodality treatment, she experienced disease progression with bone metastases after five years, followed by lymph node metastases at the ten-year mark. Subsequent treatment with the CDK4\/6i ribociclib in combination with fulvestrant resulted in disease progression approximately one year later, indicating acquired resistance. Due to progressive bone loss, denosumab was initiated for skeletal support, and bempedoic acid was later added for dyslipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This case provides a clinical basis for exploring two innovative therapeutic concepts to overcome resistance. First, we discuss the complex role of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibition. Given that leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4) functions as a decoy receptor for RANKL, we hypothesize that a patient\u2019s LGR4 expression status may dictate the efficacy and safety of denosumab, potentially serving as a predictive biomarker to personalize its use. Second, we propose that bempedoic acid, a supportive care medication, may exert a direct anti-neoplastic effect. Its dual mechanism, inhibiting ATP-citrate lyase (ACLY) to disrupt lipid synthesis and activating AMP-activated protein kinase (AMPK) to suppress mammalian target of rapamycin complex 1 (mTORC1) signaling, positions it as a potential agent to counteract the metabolic reprogramming associated with therapeutic resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case report illustrates the sequential development of acquired therapeutic resistance in the long-term management of metastatic breast cancer. Although a single clinical observation cannot establish definitive efficacy, this scenario generates compelling hypotheses for future studies. It highlights the potential need to explore biomarker-driven approaches\u2014such as evaluating LGR4 expression to guide RANKL inhibition\u2014to personalize treatment. Additionally, it raises the possibility that repurposed supportive care medications, such as bempedoic acid, might offer hypothetical anti-neoplastic benefits, warranting broader clinical validation to overcome complex resistance mechanisms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1911207","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:53:08Z","timestamp":1787719988000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Synergistic potential of RANKL and ACLY inhibition in a breast cancer patient with acquired resistance to CDK4\/6 inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"Anastasiia","family":"Samusieva","sequence":"first","affiliation":[{"name":"Department of Oncology, Shupyk National Healthcare University of Ukraine","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ielizaveta","family":"Gorodetska","sequence":"additional","affiliation":[{"name":"OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden and Helmholtz-Zentrum Dresden-Rossendorf","place":["Dresden, Germany"]},{"name":"Institute of Radiooncology-OncoRay, Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Dresden","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Socha","sequence":"additional","affiliation":[{"name":"Provincial Hospital. St. Padre Pio","place":["Przemy\u00b4sl, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliia","family":"Lytovchenko","sequence":"additional","affiliation":[{"name":"Radiology Department, Kyiv City Clinical Oncology Center","place":["Kyiv, Ukraine"]},{"name":"Department of Radiodiagnostics, Shupyk National Healthcare University of Ukraine","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kisielov","sequence":"additional","affiliation":[{"name":"Radiology Department, Kyiv City Clinical Oncology Center","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borys","family":"Dons`koi","sequence":"additional","affiliation":[{"name":"\u201dVictor Chernyshov\" Laboratory of Immunology, State Institution \"Ukrainian Center of Maternity and Childhood\", National Academy of Medical Sciences of Ukraine","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Kozeretska","sequence":"additional","affiliation":[{"name":"Independent Consultant","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasyl","family":"Lukiyanchuk","sequence":"additional","affiliation":[{"name":"OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden and Helmholtz-Zentrum Dresden-Rossendorf","place":["Dresden, Germany"]},{"name":"Institute of Radiooncology-OncoRay, Helmholtz-Zentrum Dresden-Rossendorf (HZDR) Dresden","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dubrovska","sequence":"additional","affiliation":[{"name":"OncoRay-National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden and Helmholtz-Zentrum Dresden-Rossendorf","place":["Dresden, Germany"]},{"name":"Institute of Radiooncology - OncoRay, Helmholtz-Zentrum Dresden - Rossendorf (HZDR)","place":["Dresden, Germany"]},{"name":"German Cancer Consortium (DKTK), Partner Site Dresden","place":["Dresden, Germany"]},{"name":"German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]},{"name":"National Center for Tumor Diseases (NCT), Partner Site Dresden","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeriy","family":"Cheshuk","sequence":"additional","affiliation":[{"name":"National Center for Tumor Diseases (NCT), Partner Site Dresden","place":["Dresden, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Ponomarova","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy #1, Kyiv City Clinical Oncology Center","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Kozeretska","sequence":"additional","affiliation":[{"name":"Department of General and Molecular Genetics, National Taras Shevchenko University","place":["Kyiv, Ukraine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","unstructured":"Cancer in Ukraine 2022-2023 - incidence, mortality, prevalence and other relevant statistics - bulletin of the national cancer registry of Ukraine vol.25\n          \n          Bulletin of the National Cancer Registry of Ukraine"},{"key":"B2","unstructured":"Cancer Today"},{"key":"B3","unstructured":"Seer*Explorer Application"},{"key":"B4","unstructured":"Ibrance (palbociclib), kisqali (ribociclib), and verzenio (abemaciclib): drug safety communication - due to rare but severe lung inflammation\n          \n          \n          Fda\n          \n          2024"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13050987","article-title":"Mechanisms of resistance to CDK4\/6 inhibitors and predictive biomarkers of response in HR+\/HER2-metastatic breast cancer\u2014a review of the literature","volume":"13","author":"Stanciu","year":"2023","journal-title":"Diagnostics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1038\/s41698-025-01041-1","article-title":"IL-6 predicts CDK4\/6 inhibitor resistance, identifying STAT3 as a target in HR + \/HER2-negative metastatic breast cancer","volume":"9","author":"Kettner","year":"2025","journal-title":"NPJ Precis Onc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102980","article-title":"Overcoming resistance to CDK4\/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: innovative combinations and emerging strategies","volume":"139","author":"Giugliano","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B8","unstructured":"SERENA-2: a randomised, open-label, parallel-group, multicentre phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer [clinical trial registration\n          \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63362","article-title":"Exploring the clinical impact of RANK pathway inhibition in advanced breast cancer: insights from a retrospective study on CDK4\/6 inhibitors and antiresorptive therapy","volume":"16","author":"Akdag","year":"2024","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101120","article-title":"Co-targeting RANK pathway treats and prevents acquired resistance to CDK4\/6 inhibitors in luminal breast cancer","volume":"4","author":"Gomes","year":"2023","journal-title":"Cell Rep Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ctrv.2017.10.010","article-title":"The anti-tumor effect of RANKL inhibition in Malignant solid tumors \u2013 a systematic review","volume":"62","author":"de Groot","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B12","unstructured":"Abstract P1-02-29: targeting RANK pathway in combination with CDK4\/6 inhibitors decreases the growth of palbociclib-resistant breast tumors via cancer cells and tumor microenvironment-mediated effects | clinical cancer research | american association for cancer research"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1242\/dev.033571","article-title":"Regulation of bone formation and remodeling by G-protein-coupled receptor 48","volume":"136","author":"Luo","year":"2009","journal-title":"Development"},{"key":"B14","unstructured":"RANKL regulates differentially breast cancer stem cell properties through its RANK and LGR4 receptors - sciencedirect"},{"key":"B15","unstructured":"Nilemdo | european medicines agency (EMA)\n          \n          \n          2020"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M030528","article-title":"AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism","volume":"54","author":"Pinkosky","year":"2013","journal-title":"J Lipid Res"},{"key":"B17","unstructured":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery: cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2008.03.003","article-title":"AMPK phosphorylation of raptor mediates a metabolic checkpoint","volume":"30","author":"Gwinn","year":"2008","journal-title":"Mol Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2174\/1389450115666141224125117","article-title":"ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment","volume":"16","author":"Khwairakpam","year":"2015","journal-title":"Curr Drug Targets"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/circ.144.suppl_1.13184","article-title":"Abstract 13184: ATP citrate lyase a new therapeutic target for vascular remodeling diseases","volume":"144","author":"Grobs","year":"2021","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"208","DOI":"10.53365\/nrfhh\/189500","article-title":"ATP-citrate lyase (ACLY): an extensive investigation from molecular insight to therapeutic implications","volume":"4","author":"Biju","year":"2024","journal-title":"Nat. Resour. Hum. Health"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"B23","unstructured":"Combined inhibition of STAT3 and DNA repair in palbociclib-resistant ER-positive breast cancer | clinical cancer research | american association for cancer research"},{"key":"B24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41420-023-01658-w","article-title":"Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer","volume":"9","author":"Wang","year":"2023","journal-title":"Cell Death Discov"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1911207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:53:17Z","timestamp":1787719997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1911207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1911207"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1911207","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1911207"}}